82 related articles for article (PubMed ID: 24702447)
1. The most appropriate primary outcomes to design clinical trials on Huntington's disease: meta-analyses of cohort studies and randomized placebo-controlled trials.
Salem L; Saleh N; Youssov K; Olivier A; Charles P; Scherer C; Verny C; Bachoud-Lévi AC; Maison P
Fundam Clin Pharmacol; 2014 Dec; 28(6):700-10. PubMed ID: 24702447
[TBL] [Abstract][Full Text] [Related]
2. Rate of functional decline in Huntington's disease. Huntington Study Group.
Marder K; Zhao H; Myers RH; Cudkowicz M; Kayson E; Kieburtz K; Orme C; Paulsen J; Penney JB; Siemers E; Shoulson I
Neurology; 2000 Jan; 54(2):452-8. PubMed ID: 10668713
[TBL] [Abstract][Full Text] [Related]
3. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.
; Biglan KM; Shoulson I; Kieburtz K; Oakes D; Kayson E; Shinaman MA; Zhao H; Romer M; Young A; Hersch S; Penney J; Marder K; Paulsen J; Quaid K; Siemers E; Tanner C; Mallonee W; Suter G; Dubinsky R; Gray C; Nance M; Bundlie S; Radtke D; Kostyk S; Baic C; Caress J; Walker F; Hunt V; O'Neill C; Chouinard S; Factor S; Greenamyre T; Wood-Siverio C; Corey-Bloom J; Song D; Peavy G; Moskowitz C; Wesson M; Samii A; Bird T; Lipe H; Blindauer K; Marshall F; Zimmerman C; Goldstein J; Rosas D; Novak P; Caviness J; Adler C; Duffy A; Wheelock V; Tempkin T; Richman D; Seeberger L; Albin R; Chou KL; Racette B; Perlmutter JS; Perlman S; Bordelon Y; Martin W; Wieler M; Leavitt B; Raymond L; Decolongon J; Clarke L; Jankovic J; Hunter C; Hauser RA; Sanchez-Ramos J; Furtado S; Suchowersky O; Klimek ML; Guttman M; Sethna R; Feigin A; Cox M; Shannon B; Percy A; Dure L; Harrison M; Johnson W; Higgins D; Molho E; Nickerson C; Evans S; Hobson D; Singer C; Galvez-Jimenez N; Shannon K; Comella C; Ross C; Saint-Hilaire MH; Testa C; Rosenblatt A; Hogarth P; Weiner W; Como P; Kumar R; Cotto C; Stout J; Brocht A; Watts A; Eberly S; Weaver C; Foroud T; Gusella J; MacDonald M; Myers R; Fahn S; Shults C
JAMA Neurol; 2016 Jan; 73(1):102-10. PubMed ID: 26569098
[TBL] [Abstract][Full Text] [Related]
4. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
[TBL] [Abstract][Full Text] [Related]
5. Riluzole in Huntington's disease: a 3-year, randomized controlled study.
Landwehrmeyer GB; Dubois B; de Yébenes JG; Kremer B; Gaus W; Kraus PH; Przuntek H; Dib M; Doble A; Fischer W; Ludolph AC;
Ann Neurol; 2007 Sep; 62(3):262-72. PubMed ID: 17702031
[TBL] [Abstract][Full Text] [Related]
6. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
de Yebenes JG; Landwehrmeyer B; Squitieri F; Reilmann R; Rosser A; Barker RA; Saft C; Magnet MK; Sword A; Rembratt A; Tedroff J;
Lancet Neurol; 2011 Dec; 10(12):1049-57. PubMed ID: 22071279
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.
Huntington Study Group HART Investigators
Mov Disord; 2013 Sep; 28(10):1407-15. PubMed ID: 23450660
[TBL] [Abstract][Full Text] [Related]
8. Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease.
Cubo E; González M; del Puerto I; de Yébenes JG; Arconada OF; Gabriel y Galán JM;
Mov Disord; 2012 Mar; 27(3):439-42. PubMed ID: 22162184
[TBL] [Abstract][Full Text] [Related]
9. A pilot study using nabilone for symptomatic treatment in Huntington's disease.
Curtis A; Mitchell I; Patel S; Ives N; Rickards H
Mov Disord; 2009 Nov; 24(15):2254-9. PubMed ID: 19845035
[TBL] [Abstract][Full Text] [Related]
10. Reaction time and rhythm of movement in Huntington's disease.
Martínez Pueyo A; García-Ruiz PJ; Feliz CE; Garcia Caldentey J; Del Val J; Herranz A
J Neurol Sci; 2016 Mar; 362():115-7. PubMed ID: 26944129
[TBL] [Abstract][Full Text] [Related]
11. Electrophysiological deterioration over time in patients with Huntington's disease.
Lefaucheur JP; Ménard-Lefaucheur I; Maison P; Baudic S; Cesaro P; Peschanski M; Bachoud-Lévi AC
Mov Disord; 2006 Sep; 21(9):1350-4. PubMed ID: 16721731
[TBL] [Abstract][Full Text] [Related]
12. Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.
McGarry A; Kieburtz K; Abler V; Grachev ID; Gandhi S; Auinger P; Papapetropoulos S; Hayden M
J Huntingtons Dis; 2017; 6(3):189-199. PubMed ID: 28826192
[TBL] [Abstract][Full Text] [Related]
13. A controlled trial of fluoxetine in nondepressed patients with Huntington's disease.
Como PG; Rubin AJ; O'Brien CF; Lawler K; Hickey C; Rubin AE; Henderson R; McDermott MP; McDermott M; Steinberg K; Shoulson I
Mov Disord; 1997 May; 12(3):397-401. PubMed ID: 9159735
[TBL] [Abstract][Full Text] [Related]
14. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial.
Puri BK; Leavitt BR; Hayden MR; Ross CA; Rosenblatt A; Greenamyre JT; Hersch S; Vaddadi KS; Sword A; Horrobin DF; Manku M; Murck H
Neurology; 2005 Jul; 65(2):286-92. PubMed ID: 16043801
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.
López-Sendón Moreno JL; García Caldentey J; Trigo Cubillo P; Ruiz Romero C; García Ribas G; Alonso Arias MA; García de Yébenes MJ; Tolón RM; Galve-Roperh I; Sagredo O; Valdeolivas S; Resel E; Ortega-Gutierrez S; García-Bermejo ML; Fernández Ruiz J; Guzmán M; García de Yébenes Prous J
J Neurol; 2016 Jul; 263(7):1390-400. PubMed ID: 27159993
[TBL] [Abstract][Full Text] [Related]
16. Assessing Decline: Visualising Progression in Huntington's Disease using a Clinical Dashboard with Enroll-HD Data.
Walker T; Ghosh B; Kipps C
J Huntingtons Dis; 2017; 6(2):139-147. PubMed ID: 28550266
[TBL] [Abstract][Full Text] [Related]
17. Pridopidine for the Improvement of Motor Function in Patients With Huntington's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Chen S; Liang T; Xue T; Xue S; Xue Q
Front Neurol; 2021; 12():658123. PubMed ID: 34054700
[No Abstract] [Full Text] [Related]
18. Bradykinesia in Huntington's disease. A prospective, follow-up study.
García Ruiz PJ; Hernández J; Cantarero S; Bartolomé M; Sánchez Bernardos V; García de Yébenez J
J Neurol; 2002 Apr; 249(4):437-40. PubMed ID: 11967649
[TBL] [Abstract][Full Text] [Related]
19. Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study.
McGarry A; Leinonen M; Kieburtz K; Geva M; Olanow CW; Hayden M
J Huntingtons Dis; 2020; 9(4):371-380. PubMed ID: 33164941
[TBL] [Abstract][Full Text] [Related]
20. How to Capitalize on the Retest Effect in Future Trials on Huntington's Disease.
Schramm C; Katsahian S; Youssov K; Démonet JF; Krystkowiak P; Supiot F; Verny C; Cleret de Langavant L; Bachoud-Lévi AC;
PLoS One; 2015; 10(12):e0145842. PubMed ID: 26714284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
